Acurx Prescription drugs introduced plans to allocate as much as $1 million value of Bitcoin for its treasury reserves in a strategic transfer to embrace BTC as a retailer of worth.
The choice authorized right this moment by the corporate’s board of administrators aligns with a rising development amongst firms searching for various monetary methods amid Bitcoin’s rise as a mainstream asset.
Acurx CEO David P. Luci highlighted the attraction of Bitcoin as a treasury reserve asset in his assertion:
“As demand for Bitcoin grows and Bitcoin turns into accepted as a significant and first asset class, we imagine Bitcoin will function a robust treasury reserve asset for unneeded money over the following 12 to 18 months. Its restricted provide and inflation-resistant properties make it a purposeful retailer of worth.”
Luci particularly emphasised that this transfer is solely a monetary technique and won’t influence the corporate’s ongoing drug improvement efforts.
Acurx’s resolution displays the bigger technique adopted by MicroStrategy, which first added Bitcoin to its treasury in 2020, buying 21,454 BTC at a mean value of $11,653 per coin. Since then, MicroStrategy has continued to build up Bitcoin, reaching a complete of 331,200 BTC as of this week. The corporate’s inventory is about to rise by over 500% by 2024, demonstrating the success of its Bitcoin-focused strategy.
The announcement by Acurx comes at a time when Bitcoin is buying and selling at all-time highs and analysts are predicting additional features amid President-elect Donald Trump’s guarantees of a crypto-friendly regulatory atmosphere.
*This isn’t funding recommendation.
